kabutan

KAKEN PHARMACEUTICAL CO.,LTD.(4521) Summary

4521
TSE Prime
KAKEN PHARMACEUTICAL CO.,LTD.
4,200
JPY
+65
(+1.57%)
Jan 22, 3:30 pm JST
26.44
USD
Jan 22, 1:30 am EST
Result
PTS
outside of trading hours
4,235
Jan 22, 10:36 pm JST
Summary Chart Historical News Financial Result
PER
69.1
PBR
1.08
Yield
4.52%
Margin Trading Ratio
6.68
Stock Price
Jan 22, 2026
Opening Jan 22, 9:00 am
4,140 JPY 26.12 USD
Previous Close Jan 21
4,135 JPY 26.14 USD
High Jan 22, 1:06 pm
4,205 JPY 26.54 USD
Low Jan 22, 9:00 am
4,140 JPY 26.12 USD
Volume
145,100
Trading Value
0.61B JPY 3.82M USD
VWAP
4180.77 JPY 26.32 USD
Minimum Trading Value
420,000 JPY 2,644 USD
Market Cap
0.19T JPY 1.17B USD
Number of Trades
320
Liquidity & Number of Trades
As of Jan 22, 2026
Liquidity
Slightly High
1-Year Average
617
1-Year High Apr 9, 2025
2,521
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 16, 2026 23,400 97,300 4.16
Jan 9, 2026 23,100 82,700 3.58
Dec 26, 2025 26,300 58,600 2.23
Dec 19, 2025 26,900 67,500 2.51
Dec 12, 2025 25,000 79,100 3.16
Company Profile
KAKEN PHARMACEUTICAL CO.,LTD. is a mid-sized pharmaceutical company. Its main products include joint function improvement agents and onychomycosis medications. The company also develops generic drugs and agricultural chemicals.
Sector
Pharmaceuticals
KAKEN PHARMACEUTICAL CO.,LTD. primarily engages in the pharmaceutical business, manufacturing and selling pharmaceuticals, medical devices, and agricultural chemicals. The company operates as a group that includes itself and two consolidated subsidiaries. In the pharmaceutical segment, Kaken Pharma and Asam handle manufacturing and sales. Additionally, the company is involved in the real estate business. The group as a whole focuses on the medical field while diversifying into areas such as agriculture. As a mid-sized player in the pharmaceutical industry, KAKEN PHARMACEUTICAL CO.,LTD. has established a unique product lineup and business structure, with its main products including the joint function improvement agent "ARTZ" and the onychomycosis treatment "Clenafin."